| human | Q5 |
| P213 | ISNI | 0000000385762735 |
| P1006 | Nationale Thesaurus voor Auteursnamen ID | 075206463 |
| P1207 | NUKAT ID | n2007090791 |
| P856 | official website | http://www.uwa.edu.au/people/johannes.nossent |
| P496 | ORCID iD | 0000-0002-2833-7997 |
| P1153 | Scopus author ID | 7003555505 |
| P214 | VIAF ID | 236314672 |
| P10832 | WorldCat Entities ID | E39PBJhhm7Gv8BhG776ckPwHmd |
| P108 | employer | University of Western Australia | Q1517021 |
| P735 | given name | Johannes | Q2117521 |
| Johannes | Q2117521 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q30380619 | "No Zinc deficiency but a putative immunosuppressive role for labile Zn in patients with systemic autoimmune disease". |
| Q86939242 | A remarkably useless new name in rheumatology |
| Q51125351 | APRIL levels strongly correlate with IL-17 in systemic lupus erythematosus. |
| Q72280623 | Acute chest syndrome in adult Afro-Caribbean patients with sickle cell disease. Analysis of 81 episodes among 53 patients |
| Q73574846 | Acute myelogenous leukaemia following etanercept therapy |
| Q81678363 | Antiphospholipid antibody syndrome in autoimmune hepatitis |
| Q92037992 | Association of Achieving Lupus Low Disease Activity State Fifty Percent of the Time With Both Reduced Damage Accrual and Mortality in Patients With Systemic Lupus Erythematosus |
| Q36225590 | Asymptomatic hyperuricemia is not an independent risk factor for cardiovascular events or overall mortality in the general population of the Busselton Health Study. |
| Q79324671 | B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time |
| Q45331351 | B-lymphocyte activating factor levels are increased in patients with Wegener's granulomatosis and inversely correlated with ANCA titer. |
| Q44267146 | Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis. |
| Q37282164 | CD4 cell count and CD4/CD8 ratio increase during rituximab maintenance in granulomatosis with polyangiitis patients |
| Q103740306 | Cancer diagnosis and mortality in patients with ankylosing spondylitis: A Western Australian retrospective cohort study |
| Q37981041 | Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center. |
| Q85614895 | Circulating interferon-α2 levels are increased in the majority of patients with systemic lupus erythematosus and are associated with disease activity and multiple cytokine activation |
| Q44590237 | Clinical renal involvement in Afro-Caribbean lupus patients. |
| Q67972438 | Cognitive and emotional disturbances in systemic lupus erythematosus |
| Q86495833 | Comment on 'no association of primary Sjögren's syndrome with Fcγ receptor gene variants' |
| Q74723963 | Cricoarytenoiditis in systemic lupus erythematosus |
| Q82691122 | Critical comparative analyses of anti-alpha-actinin and glomerulus-bound antibodies in human and murine lupus nephritis |
| Q44699349 | Current causes of death in systemic lupus erythematosus in Europe, 2000--2004: relation to disease activity and damage accrual. |
| Q67972433 | Daily stressors and systemic lupus erythematosus: a longitudinal analysis--first findings |
| Q79918763 | Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality |
| Q51148641 | Decreased incidence of lupus nephritis in northern Norway is linked to increased use of antihypertensive and anticoagulant therapy. |
| Q80258935 | Diagnostic impact of contemporary biomarker assays for rheumatoid arthritis |
| Q83304174 | Diagnostic value of antibodies against mutated citrullinated vimentin for rheumatoid arthritis |
| Q92421812 | Disease Activity and Patient-Reported Health Measures in Relation to Cytokine Levels in Ankylosing Spondylitis |
| Q37684873 | Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler's syndrome: a case report and literature review. |
| Q35842117 | ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients |
| Q81370046 | Early histology in ankylosing spondylitis related spondylodiscitis supports its inflammatory origin |
| Q43450070 | Effect of continuous normalization of serum complement levels on clinically evident lupus nephritis. |
| Q51129293 | Epidemiological and clinical characteristics of psoriatic arthritis in northern Norway. |
| Q50776899 | Epidemiology and outcome of adult-onset Still's disease in Northern Norway. |
| Q38124275 | Epidemiology of spondyloarthritis: a review. |
| Q80229858 | Erythroleukaemia complicating ANA-negative systemic lupus erythematosus |
| Q73034488 | Fibrosing alveolitis predating microscopic polyangiitis |
| Q38871347 | Frequency, presentation, and outcome of Takayasu arteritis in Western Australia. |
| Q89063980 | Hoffa-Synovitis and Pain Sensitization: Comment on the Article by Neogi et al |
| Q58608876 | Hospitalisation rates and characteristics for adult and childhood IgA vasculitis in Western Australia |
| Q61453809 | Hypocomplementemia as a Risk Factor for Organ Damage Accrual in Patients with Systemic Lupus Erythematosus |
| Q37679294 | IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role. |
| Q92310608 | IL-1A gene variation in relation to cytokine levels and clinical characteristics in ankylosing spondylitis |
| Q92737112 | IL23R gene variants in relation to IL17A levels and clinical phenotype in patients with ankylosing spondylitis |
| Q30417517 | Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci |
| Q46883827 | Imported case of visceral leishmaniasis presenting as pancytopenia in a Norwegian patient treated with methotrexate and etanercept for psoriasis arthritis. |
| Q80258943 | Increased ferritin response in adult Still's disease: specificity and relationship to outcome |
| Q85067660 | Increased levels of BAFF in patients with systemic lupus erythematosus are associated with acute-phase reactants, independent of BAFF genetics: a case-control study |
| Q34203097 | Increased mortality in ankylosing spondylitis is related to disease activity. |
| Q73393684 | Increased mortality in early inflammatory polyarthritis: comment on the article by Goodson et al |
| Q39367860 | Increased von Willebrand factor levels in patients with systemic lupus erythematosus reflect inflammation rather than increased propensity for platelet activation. |
| Q92774343 | Infection Rates Before and After Diagnosis of IgA Vasculitis in Childhood: A Population-wide Study Using Non-exposed Matched Controls |
| Q86050144 | Infection risks during longterm rituximab therapy change over time |
| Q80388334 | Inflammatory rheumatic disease and smoking are predictors of aortic inflammation: a controlled study of biopsy specimens obtained at coronary artery surgery |
| Q49549054 | Insulin-like growth factor-1 (IGF1) in systemic lupus erythematosus: relation to disease activity, organ damage and immunological findings. |
| Q83662486 | Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus |
| Q53170451 | Levels of transforming growth factor-beta are low in systemic lupus erythematosus patients with active disease. |
| Q100563687 | Long-Term Risk of Comorbidity after IgA Vasculitis in Childhood: A Population-Based Cohort Study |
| Q43416268 | Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. |
| Q74312793 | Long-term efficacy of azathioprine treatment for proliferative lupus nephritis |
| Q46415603 | Longstanding isolated cerebral systemic lupus erythematosus in an 8-year-old black girl. Resemblance with multiple sclerosis. |
| Q36084997 | Low copy number of the FCGR3B gene and rheumatoid arthritis: a case-control study and meta-analysis. |
| Q35645174 | Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. |
| Q83278671 | Multi-variable sensitivity and identifiability analysis for a complex environmental model in view of integrated water quantity and water quality modeling |
| Q87271382 | Not only monoclonal antibodies... |
| Q34418460 | Pancytopenia in systemic lupus erythematosus related to azathioprine. |
| Q70592684 | Panniculitis as the first manifestation of systemic lupus erythematosus: description of two cases |
| Q67933802 | Pneumatosis intestinalis in mixed connective tissue disease |
| Q81617790 | Polymorphism in the 5' regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjogren's syndrome |
| Q90781028 | Pregnancy outcomes in women with a history of immunoglobulin A vasculitis |
| Q46036146 | Prevalence, predictors and outcome of vascular damage in systemic lupus erythematosus. |
| Q90520162 | Principal component analysis reveals disconnect between regulatory cytokines and disease activity in Systemic Lupus Erythematosus |
| Q64388631 | Prior anti-dsDNA antibody status does not predict later disease manifestations in systemic lupus erythematosus |
| Q33286668 | Prognostic factors in systemic lupus erythematosus |
| Q53571665 | Pulmonary function and high-resolution CT findings five years after disease onset in patients with Wegener's granulomatosis. |
| Q36442498 | Pure red-cell aplasia in systemic lupus erythematosus. |
| Q79821007 | Quantitative salivary gland scintigraphy can distinguish patients with primary Sjøgren's syndrome during the evaluation of sicca symptoms |
| Q74048906 | Reactivation of systemic lupus erythematosus after transfer to peritoneal dialysis |
| Q37695735 | Recurrent podocytopathy in a patient with systemic lupus erythematosus. |
| Q38649705 | Renal histology in Indigenous Australians with lupus nephritis. |
| Q73086930 | Renal immunofluorescence and the prediction of renal outcome in patients with proliferative lupus nephritis |
| Q55025616 | Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. |
| Q33224257 | Rheumatoid factor by laser nephelometry and Waaler-Rose assay: prognostic value in patients with recent-onset rheumatoid arthritis. |
| Q36383052 | Rheumatoid factors do not predict cardiovascular disease and mortality in the general population in the Busselton Health Survey. |
| Q39046881 | Risk of mortality in patients with giant cell arteritis: A systematic review and meta-analysis. |
| Q82482682 | Rituximab or Cyclophosphamide in ANCA-Associated Renal Vasculitis |
| Q41748151 | SLICC/ACR Damage Index in Afro-Caribbean patients with systemic lupus erythematosus: changes in and relationship to disease activity, corticosteroid therapy, and prognosis. |
| Q104515223 | Septic arthritis due to Neisseria gonorrhoea in Western Australia |
| Q87882989 | Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis |
| Q38113507 | Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis? |
| Q37972622 | Should rheumatoid factor in rheumatoid arthritis be sent to Davy Jones's Locker? |
| Q33470628 | Single-photon-emission computed tomography of the brain in the evaluation of cerebral lupus. |
| Q58606771 | Sporadic late onset nemaline myopathy (SLONM) in an adult presenting with progressive muscle weakness |
| Q41126772 | Staphylococcus Aureus carriage and long-term Rituximab treatment for Granulomatosis with polyangiitis. |
| Q38101526 | Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review. |
| Q36995390 | Susceptibility for Lupus Nephritis by Low Copy Number of the FCGR3B Gene Is Linked to Increased Levels of Pathogenic Autoantibodies. |
| Q33562068 | Systemic lupus erythematosus. III. Observations on clinical renal involvement and follow up of renal function: Dutch experience with 110 patients studied prospectively. |
| Q73165881 | Termination of human T cell tolerance to histones by presentation of histones and polyomavirus T antigen provided that T antigen is complexed with nucleosomes |
| Q90856365 | The current role for clinical and renal histological findings as predictor for outcome in Australian patients with lupus nephritis |
| Q44263137 | The distribution of HLA-B27 subtype in patients with ankylosing spondylitis in Northern Norway. |
| Q101567665 | The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review |
| Q39838349 | The influence of ERAP1 gene variants on clinical phenotype in ankylosing spondylitis. |
| Q46125967 | The influence of the 1997 updated classification criteria for systemic lupus erythematosus: epidemiology, disease presentation, and patient management. |
| Q33417017 | Thrombopoietin levels in systemic lupus erythematosus are linked to inflammatory cytokines, but unrelated to thrombocytopenia or thrombosis. |
| Q45913031 | Tumor necrosis factor-α promoter -308/238 polymorphism association with less severe disease in ankylosing spondylitis is unrelated to serum TNF-α and does not predict TNF inhibitor response. |
| Q51246507 | Ultrasonographic assessment of joint pathology in type 2 diabetes and hyperuricemia: The Fremantle Diabetes Study Phase II. |
| Q89731149 | Validity of Self-reported Diagnosis of Rheumatoid Arthritis |
| Q53675148 | Wegener's granulomatosis mimicking psoas abscess. |
| Q40373357 | When the obvious is not the common |
| Q51510033 | Work disability in patients with ankylosing spondylitis in Norway. |
| Q72820610 | [AIDS on Curaçao: the first 6 years] |
| Q70435193 | [Acetic acid poisoning in Curaçao] |
| Q68066611 | [Cerebrovascular accidents at a young age in Rendu-Osler-Weber disease; a survey in the Netherlands Antilles] |
| Q67927850 | [Determination of antibodies against double-stranded DNA; when and which test?] |
| Q70639129 | [Lupus erythematosus; current treatment methods] |
| Q83326918 | [New criteria for rheumatoid arthritis] |
| Q79961951 | [Systemic lupus erythematosus and pregnancy] |
| Q53850284 | [Treatment with etanercept in chronic polyarthritis]. |
Search more.